董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James C. Foster | 男 | Chairman, President and Chief Executive Officer | 74 | 1347.36万美元 | 31.27 | 2025-09-29 |
| Virginia M. Wilson | 女 | Director | 70 | 34.55万美元 | 1.22 | 2025-09-29 |
| Nancy C. Andrews | 女 | Director | 66 | 34.05万美元 | 1.18 | 2025-09-29 |
| George Llado | 男 | Director | 59 | 32.55万美元 | 1.01 | 2025-09-29 |
| Reshema Kemps Polanco | 女 | Director | 52 | 41.40万美元 | 0.27 | 2025-09-29 |
| Martin Mackay | 男 | Director | 68 | 34.05万美元 | 2.07 | 2025-09-29 |
| Craig B. Thompson | 男 | Director | 72 | 32.05万美元 | 0.50 | 2025-09-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James C. Foster | 男 | Chairman, President and Chief Executive Officer | 74 | 1347.36万美元 | 31.27 | 2025-09-29 |
| Birgit Girshick | 女 | Executive Vice President and Chief Operating Officer | 55 | 505.65万美元 | 6.13 | 2025-09-29 |
| Joseph W. LaPlume | 男 | Senior Corporate Counsel, Senior Vice President | 51 | 298.10万美元 | 2.12 | 2025-09-29 |
| Victoria Creamer | 女 | Executive Vice President | 55 | 280.66万美元 | 2.18 | 2025-09-29 |
| Shannon Parisotto | 女 | Executive Vice President | 51 | 未披露 | 未持股 | 2025-09-29 |
| Michael G. Knell | -- | Senior Vice President and Chief Accounting Officer, Chief Financial Officer | -- | 未披露 | 未持股 | 2025-09-29 |
董事简历
中英对照 | 中文 | 英文- James C. Foster
-
James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
James C. Foster,joined in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989. - James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
- James C. Foster,joined in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.
- Virginia M. Wilson
-
Virginia M. Wilson，TIAA退休的高级执行副总裁兼首席财务官，负责领导财务和精算职能。在2010年加入TIAA之前，Wilson女士曾担任Wyndham Worldwide Corporation执行副总裁兼首席财务官，在Wyndham于2006年从Cendant Corporation分拆后领导其财务和技术组织。此前，她曾担任Cendant的执行副总裁兼首席会计官，还曾担任大都会人寿公司和Transamerica人寿保险部门的高级副总裁兼公司财务总监。Wilson女士的职业生涯始于德勤，是一名注册会计师。她是Carrier Global Corporation现任董事会成员和Conduent Incorporated前任董事会成员。Wilson女士自2019年10月起担任董事。Wilson女士为董事会带来了30多年的财务管理经验，负责监督大型跨国组织的会计、精算、税务以及财务规划和报告职能。此外，由于她的注册会计师背景和之前担任过上市公司首席财务官的服务，Wilson女士有资格成为SEC准则下的“审计委员会财务专家”。
Virginia M. Wilson,Retired Senior Executive Vice President and Chief Financial Officer of TIAA, where she was responsible for leading finance and actuarial functions. Prior to joining TIAA in 2010, Ms. Wilson served as Executive Vice President and Chief Financial Officer of Wyndham Worldwide Corporation, leading Wyndham's finance and technology organizations following its spin-off from Cendant Corporation in 2006. Previously, she served as Cendant's Executive Vice President and Chief Accounting Officer and also served as Senior Vice President and Corporate Controller of both MetLife, Inc. and Transamerica's life insurance division. Ms. Wilson began her career at Deloitte and is a Certified Public Accountant. She is a current member of the board of directors of Carrier Global Corporation and a former member of the board of directors of Conduent Incorporated. Ms. Wilson has been a director since October 2019. - Virginia M. Wilson，TIAA退休的高级执行副总裁兼首席财务官，负责领导财务和精算职能。在2010年加入TIAA之前，Wilson女士曾担任Wyndham Worldwide Corporation执行副总裁兼首席财务官，在Wyndham于2006年从Cendant Corporation分拆后领导其财务和技术组织。此前，她曾担任Cendant的执行副总裁兼首席会计官，还曾担任大都会人寿公司和Transamerica人寿保险部门的高级副总裁兼公司财务总监。Wilson女士的职业生涯始于德勤，是一名注册会计师。她是Carrier Global Corporation现任董事会成员和Conduent Incorporated前任董事会成员。Wilson女士自2019年10月起担任董事。Wilson女士为董事会带来了30多年的财务管理经验，负责监督大型跨国组织的会计、精算、税务以及财务规划和报告职能。此外，由于她的注册会计师背景和之前担任过上市公司首席财务官的服务，Wilson女士有资格成为SEC准则下的“审计委员会财务专家”。
- Virginia M. Wilson,Retired Senior Executive Vice President and Chief Financial Officer of TIAA, where she was responsible for leading finance and actuarial functions. Prior to joining TIAA in 2010, Ms. Wilson served as Executive Vice President and Chief Financial Officer of Wyndham Worldwide Corporation, leading Wyndham's finance and technology organizations following its spin-off from Cendant Corporation in 2006. Previously, she served as Cendant's Executive Vice President and Chief Accounting Officer and also served as Senior Vice President and Corporate Controller of both MetLife, Inc. and Transamerica's life insurance division. Ms. Wilson began her career at Deloitte and is a Certified Public Accountant. She is a current member of the board of directors of Carrier Global Corporation and a former member of the board of directors of Conduent Incorporated. Ms. Wilson has been a director since October 2019.
- Nancy C. Andrews
-
Nancy C. Andrews，杜克大学儿科教授、药理学和癌症生物学教授（2007年以来），2013年至2020年纳纳琳·h·杜克捐赠的主席。从2007年到2017年，Andrews博士担任杜克大学医学院院长和杜克大学学术事务副校长。从2003年到2007年，她担任哈佛大学医学院（Harvard University Medical School）基础科学和研究生研究主任和儿科教授。从1999年到2003年，她担任哈佛-麻省理工学院（Harvard-Massachusetts Institute of Technology）主任。项目，以及其MSTP赠款的主要研究者。从1993年到2006年，她是霍华德休斯医学研究所的生物医学研究员。她是MIT公司的执行委员会成员，美国艺术与科学学院的董事会主席，以及Dyne Therapeutics的科学顾问委员会成员。她是the National Academy of Medicine和the National Academy of Sciences的当选成员，目前任职于the National Academy of Sciences的理事会。她是Burroughs Wellcome Fund的前董事会主席，也是National Institutes of Health的科学管理审查委员会的前成员。她还担任Novartis International AG和Maze Therapeutics的董事会成员。Andrews博士自2020年2月起担任Charles River Laboratories International, Inc.的董事会成员。
Nancy C. Andrews,Executive Vice President and Chief Scientific Officer at Boston Children's Hospital since December 2021. Professor in Residence at Harvard Medical School since November 2023. Served as Professor of Pediatrics and Professor of Pharmacology & Cancer Biology at Duke University from 2007 to December 2021 (and the Nanaline H. Duke endowed chair from 2013 to 2020). From 2007 to 2017, Dr. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University. From 2003 to 2007, she served as Dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard-Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a biomedical research investigator of the Howard Hughes Medical Institute. She is a member of the Scientific Advisory Board of Dyne Therapeutics. She is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine and the National Academy of Sciences, and currently serves as Home Secretary for the National Academy of Sciences. Dr. Andrews previously served on the Executive Committee of the MIT Corporation and as Chair of the Board of Directors of the American Academy of Arts and Sciences. She is a former Chair of the Board of Directors of the Burroughs Wellcome Fund and a former member of the Scientific Management Review Board at the National Institutes of Health. Dr. Andrews also serves on the boards of directors of Novartis International AG and Maze Therapeutics. Dr. Andrews has been a director since February 2020. - Nancy C. Andrews，杜克大学儿科教授、药理学和癌症生物学教授（2007年以来），2013年至2020年纳纳琳·h·杜克捐赠的主席。从2007年到2017年，Andrews博士担任杜克大学医学院院长和杜克大学学术事务副校长。从2003年到2007年，她担任哈佛大学医学院（Harvard University Medical School）基础科学和研究生研究主任和儿科教授。从1999年到2003年，她担任哈佛-麻省理工学院（Harvard-Massachusetts Institute of Technology）主任。项目，以及其MSTP赠款的主要研究者。从1993年到2006年，她是霍华德休斯医学研究所的生物医学研究员。她是MIT公司的执行委员会成员，美国艺术与科学学院的董事会主席，以及Dyne Therapeutics的科学顾问委员会成员。她是the National Academy of Medicine和the National Academy of Sciences的当选成员，目前任职于the National Academy of Sciences的理事会。她是Burroughs Wellcome Fund的前董事会主席，也是National Institutes of Health的科学管理审查委员会的前成员。她还担任Novartis International AG和Maze Therapeutics的董事会成员。Andrews博士自2020年2月起担任Charles River Laboratories International, Inc.的董事会成员。
- Nancy C. Andrews,Executive Vice President and Chief Scientific Officer at Boston Children's Hospital since December 2021. Professor in Residence at Harvard Medical School since November 2023. Served as Professor of Pediatrics and Professor of Pharmacology & Cancer Biology at Duke University from 2007 to December 2021 (and the Nanaline H. Duke endowed chair from 2013 to 2020). From 2007 to 2017, Dr. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University. From 2003 to 2007, she served as Dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School. From 1999 to 2003, she served as director of the Harvard-Massachusetts Institute of Technology M.D./Ph.D. Program, and the principal investigator of its MSTP grant. From 1993 to 2006, she was a biomedical research investigator of the Howard Hughes Medical Institute. She is a member of the Scientific Advisory Board of Dyne Therapeutics. She is an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine and the National Academy of Sciences, and currently serves as Home Secretary for the National Academy of Sciences. Dr. Andrews previously served on the Executive Committee of the MIT Corporation and as Chair of the Board of Directors of the American Academy of Arts and Sciences. She is a former Chair of the Board of Directors of the Burroughs Wellcome Fund and a former member of the Scientific Management Review Board at the National Institutes of Health. Dr. Andrews also serves on the boards of directors of Novartis International AG and Maze Therapeutics. Dr. Andrews has been a director since February 2020.
- George Llado
-
George Llado，自2015年起担任Alexion Pharmaceuticals, Inc.的高级副总裁兼首席信息官。作为一个拥有超过30年制药业务、技术和网络安全经验的行业资深人士，Llado先生和他在Alexion的全球团队开发和实施创新技术，并使数据驱动的洞察力贯穿Alexion的研发、商业、制造运营和供应链职能。加入Alexion之前，Llado先生担任Merck and Co.的副总裁和业务线CIO，在那里他领导公司制造部门的IT解决方案的规划和开发。在此之前，他是默克公司的副总裁，负责全球商业组织和各种企业一般与行政职能的IT和业务线CIO。他领导了默克和先灵葆雅跨IT和共享业务服务组织的大规模合并整合。他还在默克公司担任多个其他职位，并在花旗银行（Citibank, N.A。）工作。他任职于国家妇女与信息技术中心（NCWIT）董事会，他是董事会发展委员会的成员，并赞助了“计算机顾问”等重要项目，这些项目提高了该组织的会员资格。他还任职于Temple Fox Business School IT顾问委员会。Llado先生自2020年10月起担任董事。
George Llado,Former Senior Vice President and Chief Information Officer (CIO) of Alexion Pharmaceuticals, Inc. As an industry veteran with over 30 years of pharmaceutical business and technology and cyber-security experience, Mr. Llado, through his time at Alexion, contributed to the development and implementation of innovative technology, enabling data-driven insights across Alexion's R&D, Commercial, Manufacturing Operations and Supply Chain functions. Prior to joining Alexion, Mr. Llado served as Vice President and business line CIO for Merck and Co., where he led the planning and development of IT solutions for the company's Manufacturing Division. Before that, he was Merck's Vice President, IT and business line CIO for the Global Commercial Organization and various corporate G&A functions. He led the large-scale merger integration of Merck and Schering-Plough across the IT and Shared Business Services organizations. He also held several other positions of increasing responsibility at Merck, and previously worked at Citibank, N.A. Mr. Llado serves on the Tracelink Inc. and the National Center for Women & Information Technology (NCWIT) Board. He also serves on the Temple Fox Business School IT Advisory Board. Mr. Llado has been a director since October 2020. - George Llado，自2015年起担任Alexion Pharmaceuticals, Inc.的高级副总裁兼首席信息官。作为一个拥有超过30年制药业务、技术和网络安全经验的行业资深人士，Llado先生和他在Alexion的全球团队开发和实施创新技术，并使数据驱动的洞察力贯穿Alexion的研发、商业、制造运营和供应链职能。加入Alexion之前，Llado先生担任Merck and Co.的副总裁和业务线CIO，在那里他领导公司制造部门的IT解决方案的规划和开发。在此之前，他是默克公司的副总裁，负责全球商业组织和各种企业一般与行政职能的IT和业务线CIO。他领导了默克和先灵葆雅跨IT和共享业务服务组织的大规模合并整合。他还在默克公司担任多个其他职位，并在花旗银行（Citibank, N.A。）工作。他任职于国家妇女与信息技术中心（NCWIT）董事会，他是董事会发展委员会的成员，并赞助了“计算机顾问”等重要项目，这些项目提高了该组织的会员资格。他还任职于Temple Fox Business School IT顾问委员会。Llado先生自2020年10月起担任董事。
- George Llado,Former Senior Vice President and Chief Information Officer (CIO) of Alexion Pharmaceuticals, Inc. As an industry veteran with over 30 years of pharmaceutical business and technology and cyber-security experience, Mr. Llado, through his time at Alexion, contributed to the development and implementation of innovative technology, enabling data-driven insights across Alexion's R&D, Commercial, Manufacturing Operations and Supply Chain functions. Prior to joining Alexion, Mr. Llado served as Vice President and business line CIO for Merck and Co., where he led the planning and development of IT solutions for the company's Manufacturing Division. Before that, he was Merck's Vice President, IT and business line CIO for the Global Commercial Organization and various corporate G&A functions. He led the large-scale merger integration of Merck and Schering-Plough across the IT and Shared Business Services organizations. He also held several other positions of increasing responsibility at Merck, and previously worked at Citibank, N.A. Mr. Llado serves on the Tracelink Inc. and the National Center for Women & Information Technology (NCWIT) Board. He also serves on the Temple Fox Business School IT Advisory Board. Mr. Llado has been a director since October 2020.
- Reshema Kemps Polanco
-
Reshema Kemps Polanco，拥有25年的制药行业经验，目前担任Novartis US（全球生物制药公司Novartis AG的美国业务）的执行副总裁兼首席商务官。在此职位上，她负责四个治疗领域的端到端商业化，包括肿瘤学、免疫学、神经病学和心血管/肾脏/代谢疾病。在2021年重新加入Novartis之前，Kemps-Polanco女士从2014年到2021年在Johnson & Johnson担任多个领导职务，最近担任Janssen U.S. Cardiovascular & Metabolism和Janssen Pharmaceuticals Puerto Rico的总裁。在此职位上，她负责开发和交付业务战略，并推动这些业务的增长计划。
Reshema Kemps Polanco,is Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company Novartis AG, responsible for end-to-end commercialization across four therapeutic areas. Ms. Kemps-Polanco returned to Novartis in 2021 as EVP & US Head, Novartis Oncology. Prior to rejoining Novartis, Ms. Kemps-Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Ms. Kemps-Polanco began her pharmaceutical industry career at Novartis in 2012 in sales and held management positions of increasing responsibility. Ms. Kemps-Polanco is a board member of the Healthcare Leadership Council (HLC), a member of the Healthcare Businesswomen's Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps-Polanco has been a board member since January 2024. - Reshema Kemps Polanco，拥有25年的制药行业经验，目前担任Novartis US（全球生物制药公司Novartis AG的美国业务）的执行副总裁兼首席商务官。在此职位上，她负责四个治疗领域的端到端商业化，包括肿瘤学、免疫学、神经病学和心血管/肾脏/代谢疾病。在2021年重新加入Novartis之前，Kemps-Polanco女士从2014年到2021年在Johnson & Johnson担任多个领导职务，最近担任Janssen U.S. Cardiovascular & Metabolism和Janssen Pharmaceuticals Puerto Rico的总裁。在此职位上，她负责开发和交付业务战略，并推动这些业务的增长计划。
- Reshema Kemps Polanco,is Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company Novartis AG, responsible for end-to-end commercialization across four therapeutic areas. Ms. Kemps-Polanco returned to Novartis in 2021 as EVP & US Head, Novartis Oncology. Prior to rejoining Novartis, Ms. Kemps-Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico. Ms. Kemps-Polanco began her pharmaceutical industry career at Novartis in 2012 in sales and held management positions of increasing responsibility. Ms. Kemps-Polanco is a board member of the Healthcare Leadership Council (HLC), a member of the Healthcare Businesswomen's Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps-Polanco has been a board member since January 2024.
- Martin Mackay
-
Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017. - Martin Mackay博士。Mackay是Rallybio Corporation的联合创始人、执行主席、前首席执行官和现任董事，Rallybio Corporation是一家生物技术公司，于2018年1月注册成立，最近于2021年7月成为上市公司。2013年5月至2017年6月，Mackay博士担任Alexion Pharmaceuticals， Inc.的全球研发主管；2010年7月至2013年1月，Mackay博士担任AstraZeneca PLC的研发总裁，在那里他领导研发组织，并全面负责从其管道交付新产品。Mackay博士自2018年3月起担任Novo Nordisk的董事。从2020年10月到2022年4月，Mackay博士担任5：01 Acquisition Corp.的董事，这是一家空白支票公司，其主要目的是实现业务合并，从未从事经营活动。Mackay博士自2017年7月起担任公司董事。Mackay在全球制药和生物技术公司领导研发组织的丰富经验为Charles River Laboratories International， Inc.提供了独特的专业知识组合。
- Martin Mackay,is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and, from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay has served as a director of Novo Nordisk since March 2018 and SpringWorks Therapeutics since 2024. From October 2020 through April 2022, Dr. Mackay served as a director of 5:01 Acquisition Corp. Dr. Mackay has been a director of the Company since July 2017.
- Craig B. Thompson
-
Craig B. Thompson， 2010年11月起，他担任Memorial Sloan-Kettering Cancer Center的总裁和首席行政官；2006年至2010年，他担任宾夕法尼亚大学医学院Abramson Cancer Center的董事；1999年至2011年，他担任宾夕法尼亚大学医疗和癌症学教授。他是American Academy of Arts and Sciences研究员、Howard Hughes Medical Institute医学顾问委员会、National Academy of Sciences以及National Academy of Sciences的医学协会成员。他是Merck & Co的董事。2013年起，他成为董事。
Craig B. Thompson,Former President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center from 2010 to 2022, where he continues to oversee the Craig Thompson Lab;Co-founder of Agios Pharmaceuticals, Inc.;Former director of Merck & Co., Inc. - Craig B. Thompson， 2010年11月起，他担任Memorial Sloan-Kettering Cancer Center的总裁和首席行政官；2006年至2010年，他担任宾夕法尼亚大学医学院Abramson Cancer Center的董事；1999年至2011年，他担任宾夕法尼亚大学医疗和癌症学教授。他是American Academy of Arts and Sciences研究员、Howard Hughes Medical Institute医学顾问委员会、National Academy of Sciences以及National Academy of Sciences的医学协会成员。他是Merck & Co的董事。2013年起，他成为董事。
- Craig B. Thompson,Former President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center from 2010 to 2022, where he continues to oversee the Craig Thompson Lab;Co-founder of Agios Pharmaceuticals, Inc.;Former director of Merck & Co., Inc.
高管简历
中英对照 | 中文 | 英文- James C. Foster
James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
James C. Foster,joined in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.- James C. Foster，1976年加入Charles River Laboratories International, Inc.，担任总法律顾问。Foster先生在任职期间曾担任多个职员和管理职务，并于1992年被任命为首席执行官兼总裁，于2000年被任命为Charles River Laboratories International, Inc.董事长。
- James C. Foster,joined in 1976 as General Counsel and over his tenure has held various staff and managerial positions. Mr. Foster was named President in 1991, Chief Executive Officer in 1992, and Chair in 2000. Mr. Foster has been a director since 1989.
- Birgit Girshick
Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
Birgit Girshick,joined in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc. RMS Germany and RMS Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the RMS Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc. then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc. Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities.- Birgit Girshick于1989年加入Charles River Laboratories International, Inc.，最初在RMS德国和RMS禽类疫苗业务担任越来越重要的职务。2004年，她被提升为RMS禽类疫苗服务业务的总经理。她于2009年被任命为RMS流程改进执行董事，并于2010年被任命为全球生物制药服务公司副总裁。2013年，Girshick女士晋升为公司高级副总裁，负责研究模型和生物制品测试解决方案。2016年，Girshick女士负责领导将WIL研究整合到Charles River Laboratories International, Inc.的安全评估业务。此外，Girshick女士于2016年担任公司高级副总裁，负责全球发现服务。她于2018年2月被任命为公司执行副总裁，负责全球发现和安全评估，并于2018年8月另外负责Charles River Laboratories International, Inc.的生物制品测试解决方案和禽流感疫苗服务业务。
- Birgit Girshick,joined in 1989 and originally held positions of increasing responsibility in Charles River Laboratories International, Inc. RMS Germany and RMS Avian Vaccine businesses. In 2004, Ms. Girshick was promoted to General Manager of the RMS Avian Vaccine Services business. She was named Executive Director, RMS Process Improvement in 2009, and Corporate Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick was tasked with leading the integration of WIL Research into Charles River Laboratories International, Inc. then Safety Assessment business. Also, in 2016, Ms. Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. In February 2018, Ms. Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment and in August 2018, additionally took on responsibility for Charles River Laboratories International, Inc. Biologics Solutions and Avian Vaccine Services business. In November 2021, Ms. Girshick was promoted to Chief Operating Officer of the Company, adding the Research Models and Services, Microbial Solutions and CDMO businesses as well as the Global Information Technologies group to her responsibilities.
- Joseph W. LaPlume
Joseph W. LaPlume，2005年加入Charles River Laboratories International，Inc.，担任高级公司法律顾问。他于2010年成为副总法律顾问，2011年成为公司发展副总裁，2014年成为高级副总裁，2019年1月成为发展和战略执行副总裁。在目前的职位上，他负责监督跨业务部门和地域的战略规划和公司发展活动的各个方面。在加入Charles River Laboratories International, Inc.之前，LaPlume先生是GTECH公司的公司律师，并在Mintz Levin和Goulston & Storrs律师事务所从事私人执业。
Joseph W. LaPlume,joined in 2005 as Senior Corporate Counsel. He became Deputy General Counsel in 2010, Vice President, Corporate Development in 2011, Senior Vice President in 2014 and Corporate Executive Vice President, Corporate Development and Strategy in January 2019. In his current role, he oversees all aspects of strategic planning and corporate development activities across business segments and geographies. Prior to joining Charles River Laboratories International, Inc. , Mr. LaPlume was a corporate lawyer at GTECH Corporation and in private practice at the law firms of Mintz Levin and Goulston & Storrs.- Joseph W. LaPlume，2005年加入Charles River Laboratories International，Inc.，担任高级公司法律顾问。他于2010年成为副总法律顾问，2011年成为公司发展副总裁，2014年成为高级副总裁，2019年1月成为发展和战略执行副总裁。在目前的职位上，他负责监督跨业务部门和地域的战略规划和公司发展活动的各个方面。在加入Charles River Laboratories International, Inc.之前，LaPlume先生是GTECH公司的公司律师，并在Mintz Levin和Goulston & Storrs律师事务所从事私人执业。
- Joseph W. LaPlume,joined in 2005 as Senior Corporate Counsel. He became Deputy General Counsel in 2010, Vice President, Corporate Development in 2011, Senior Vice President in 2014 and Corporate Executive Vice President, Corporate Development and Strategy in January 2019. In his current role, he oversees all aspects of strategic planning and corporate development activities across business segments and geographies. Prior to joining Charles River Laboratories International, Inc. , Mr. LaPlume was a corporate lawyer at GTECH Corporation and in private practice at the law firms of Mintz Levin and Goulston & Storrs.
- Victoria Creamer
Victoria Creamer于2019年加入Charles River Laboratories International, Inc.，担任高级副总裁兼首席人力资源官。2020年，Creamer女士晋升为公司执行副总裁。加入公司之前，Creamer女士在ITT和IBM各担任高级管理人力资源职位。
Victoria Creamer,joined in January 2019 as Senior Vice President, Chief People Officer. In October 2020, Ms. Creamer was promoted to Corporate Executive Vice President. Prior to joining the Company, from 2015 to December 2018, Ms. Creamer served as Senior Vice President, Human Resources and Communications for ITT, Inc., a manufacturing company, where she was responsible for providing vision, leadership and execution of the company's people and communications strategies.- Victoria Creamer于2019年加入Charles River Laboratories International, Inc.，担任高级副总裁兼首席人力资源官。2020年，Creamer女士晋升为公司执行副总裁。加入公司之前，Creamer女士在ITT和IBM各担任高级管理人力资源职位。
- Victoria Creamer,joined in January 2019 as Senior Vice President, Chief People Officer. In October 2020, Ms. Creamer was promoted to Corporate Executive Vice President. Prior to joining the Company, from 2015 to December 2018, Ms. Creamer served as Senior Vice President, Human Resources and Communications for ITT, Inc., a manufacturing company, where she was responsible for providing vision, leadership and execution of the company's people and communications strategies.
- Shannon Parisotto
Shannon Parisotto托于2000年加入Charles River Laboratories International，Inc.，参与内华达州股份有限公司的Charles River实验室国际业务。Parisotto女士通过了一系列责任越来越大的财务管理职位，并于2010年晋升为财务部临床前服务公司副总裁。在这一职位上，Parisotto女士负责全球临床前服务业务的财务运营。从2011年开始，Parisotto女士的角色扩大到包括其他业务部门，2015年，她晋升为新设立的全球运营公司高级副总裁兼财务总监，在那里她与Charles River的业务部门合作制定和实施业务战略。2020年，Parisotto女士晋升为全球安全评估公司高级副总裁，负责领导公司的全球安全评估组织，并将业务定位为持续、长期增长和成功。2022年10月，Parisotto女士晋升为公司执行副总裁，并承担了对发现服务业务的额外监督，以领导其战略愿景和运营增长，并加强业务之间以及与全球发现和安全评估部门客户之间的协同作用。Parisotto女士拥有内华达大学雷诺分校会计学学士学位，凤凰大学工商管理硕士学位，是一名注册会计师。
Shannon Parisotto,joined in 2000 in Nevada operation. Ms. Parisotto progressed through a number of finance management positions of increasing responsibility, and in 2010, was promoted to Corporate Vice President, Preclinical Services, Finance. In this role, Ms. Parisotto was responsible for the financial operations of the global Preclinical Services business. Beginning in 2011, Ms. Parisotto's role was expanded to include additional business segments, and in 2015, she was promoted to the newly created position of Corporate Senior Vice President & Controller, Global Operations, where she worked collaboratively with Charles River's business units to develop and implement business strategies. In 2020, Ms. Parisotto was promoted to Corporate Senior Vice President, Global Safety Assessment, where she was responsible for leading the Company's global Safety Assessment organization, and positioning the business for continued, long-term growth and success. In October 2022, Ms. Parisotto was promoted to Corporate Executive Vice President, and assumed the additional oversight of Charles River Laboratories International, Inc. then Discovery Services business to lead its strategic vision and operational growth, as well as enhance the synergies between the businesses and with clients across the global DSA segment. Ms. Parisotto holds a B.S. in Accounting from the University of Nevada, Reno, an M.B.A. from the University of Phoenix, and is a Certified Public Accountant.- Shannon Parisotto托于2000年加入Charles River Laboratories International，Inc.，参与内华达州股份有限公司的Charles River实验室国际业务。Parisotto女士通过了一系列责任越来越大的财务管理职位，并于2010年晋升为财务部临床前服务公司副总裁。在这一职位上，Parisotto女士负责全球临床前服务业务的财务运营。从2011年开始，Parisotto女士的角色扩大到包括其他业务部门，2015年，她晋升为新设立的全球运营公司高级副总裁兼财务总监，在那里她与Charles River的业务部门合作制定和实施业务战略。2020年，Parisotto女士晋升为全球安全评估公司高级副总裁，负责领导公司的全球安全评估组织，并将业务定位为持续、长期增长和成功。2022年10月，Parisotto女士晋升为公司执行副总裁，并承担了对发现服务业务的额外监督，以领导其战略愿景和运营增长，并加强业务之间以及与全球发现和安全评估部门客户之间的协同作用。Parisotto女士拥有内华达大学雷诺分校会计学学士学位，凤凰大学工商管理硕士学位，是一名注册会计师。
- Shannon Parisotto,joined in 2000 in Nevada operation. Ms. Parisotto progressed through a number of finance management positions of increasing responsibility, and in 2010, was promoted to Corporate Vice President, Preclinical Services, Finance. In this role, Ms. Parisotto was responsible for the financial operations of the global Preclinical Services business. Beginning in 2011, Ms. Parisotto's role was expanded to include additional business segments, and in 2015, she was promoted to the newly created position of Corporate Senior Vice President & Controller, Global Operations, where she worked collaboratively with Charles River's business units to develop and implement business strategies. In 2020, Ms. Parisotto was promoted to Corporate Senior Vice President, Global Safety Assessment, where she was responsible for leading the Company's global Safety Assessment organization, and positioning the business for continued, long-term growth and success. In October 2022, Ms. Parisotto was promoted to Corporate Executive Vice President, and assumed the additional oversight of Charles River Laboratories International, Inc. then Discovery Services business to lead its strategic vision and operational growth, as well as enhance the synergies between the businesses and with clients across the global DSA segment. Ms. Parisotto holds a B.S. in Accounting from the University of Nevada, Reno, an M.B.A. from the University of Phoenix, and is a Certified Public Accountant.
- Michael G. Knell
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介